Investor Clal Biotechnology Industries Ltd.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Clal Biotechnology Industries Ltd. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2024-04-10 13D/A ELTX / Elicio Therapeutics, Inc. 599,197 481,727
2024-03-20 13D/A ELTX / Elicio Therapeutics, Inc. 689,569 599,197
2023-12-27 13D/A ELTX / Elicio Therapeutics, Inc. 689,569 689,569
2023-08-30 13D/A ELTX / Elicio Therapeutics, Inc. 689,569 689,569
2023-06-12 13D ELTX / Elicio Therapeutics, Inc. 689,569
2023-06-02 13D US77867P1049 / Roth Ch Acquisition IV Co. 4,584,422
2019-02-12 13G/A MDWD / MediWound Ltd. 9,429,555 9,429,555
2018-02-06 13G/A MDWD / MediWound Ltd. 9,389,555 9,429,555
2017-02-07 13G/A MDWD / MediWound Ltd. 9,389,555
2015-02-12 13G MDWD / MediWound Ltd. 9,789,555
2013-01-08 13D/A CMMB / Chemomab Therapeutics Ltd. - Depositary Receipt (Common Stock) 65,948,897
2012-12-17 13D/A CMMB / Chemomab Therapeutics Ltd. - Depositary Receipt (Common Stock) 65,948,897
2012-08-16 13D CMMB / Chemomab Therapeutics Ltd. - Depositary Receipt (Common Stock) 29,043,897
2012-08-07 13D/A 29,043,897
2012-03-07 13D 18,065,266